Portola Pharmaceuticals (PTLA) has risen sharply, recording gains of 7.99% in the past 4 weeks. However, the stock has corrected -2.11% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 8.57% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 0.49% and the 50-Day Moving Average is 3.4%.The 200 Day SMA reached 18.91%
Portola Pharmaceuticals (NASDAQ:PTLA): After opening at $22.71, the stock dipped to an intraday low of $22.48 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $23.04 and the buying power remained strong till the end. The stock closed at $22.71 for the day, a gain of 0.09% for the day session. The total traded volume was 795,789. The stocks close on the previous trading day was $22.71.
Portola Pharmaceuticals (PTLA) : 2 Wall Street analysts covering Portola Pharmaceuticals (PTLA) believe that the average level the stock could reach for the short term is $34. The maximum price target given is $40 and the minimum target for short term is around $28, hence the standard deviation is calculated at $8.49.
Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Companys two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company has a program of selective Syk inhibitors, which is partnered with Biogen Idec Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa. Andexanet alfa is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor. Cerdulatinib is an orally available, potent dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor.